Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL)

•A phase II randomized study of gefitinib versus gefitinib plus olaparib in 182 EGFR-mutation positive NSCLC patients.•The study included patients from Spain and Mexico.•Median progression-free survival was 10.9 months in the gefitinib compared to 12.8 months in the gefitinib plus olaparib arm. Prog...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2020-12, Vol.150, p.62-69
Hauptverfasser:	Garcia-Campelo, Rosario, Arrieta, Oscar, Massuti, Bartomeu, Rodriguez-Abreu, Delvys, Granados, Ana Laura Ortega, Majem, Margarita, Vicente, David, Lianes, Pilar, Bosch-Barrera, Joaquim, Insa, Amelia, Dómine, Manuel, Reguart, Noemí, Guirado, María, Sala, María Ángeles, Vázquez-Estevez, Sergio, Caro, Reyes Bernabé, Drozdowskyj, Ana, Verdú, Ana, Karachaliou, Niki, Molina-Vila, Miguel Angel, Rosell, Rafael
Format:	Artikel
Sprache:	eng
Schlagworte:	EGFR Gefitinib Non-small-cell lung cancer Olaparib
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!